

Healing effectiveness of Algosteril vs Aquacel Extra in pilonidal sinuses

Submission date 27/07/2023	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 28/07/2023	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 04/04/2025	Condition category Skin and Connective Tissue Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Pilonidal disease is caused by the penetration of hairs into dimples in the gluteal (buttock) cleft and may present as an acute abscess or chronic suppuration (pus). In the chronic phase, surgery is recommended. The technique of wide excision without closure is favoured by French surgeons: under anaesthesia, the infected tissue is removed, then the wound is left open for directed healing (budding tissue develops and fills the lesion from depth to surface). Wide excision of the pilonidal sinus has a 95% recurrence-free cure rate. However, it is a high-impact procedure for patients, requiring daily, sometimes painful nursing care over a prolonged period (typically 2-3 months). The aim of this study is to demonstrate that the speed of budding tissue development is faster with Algosteril compared with Aquacel Extra.

Who can participate?

Patients with a pilonidal sinus that needs to be excised

What does the study involve?

Patients will be randomly assigned to either the Algostéril group or the Aquacel Extra group. After surgery, the excision filling will be evaluated at weeks 3 and 6.

What are the possible benefits and risks of participating?

Participants treated with Algostéril may benefit from a reduction of the duration of healing. No risks have been identified. Algosteril and Aquacel Extra will be used as indicated.

Where is the study run from?

The study will be run from several French hospitals

When is the study starting and how long is it expected to run for?

December 2022 to July 2026

Who is funding the study?

Laboratoires Brothier (France)

Who is the main contact?
Mélanie Angot, melanie.angot@brothier.com

Contact information

Type(s)

Public

Contact name

Mrs Mélanie Angot

Contact details

Brothier
41 rue de Neuilly
Nanterre
France
92735
+33 (0)1 56 38 30 00
recherche.clinique@brothier.com

Additional identifiers

Clinical Trials Information System (CTIS)

2022-A02722-41

Protocol serial number

RCT/PILO-ALGm/ALGc-12.2022

Study information

Scientific Title

Multicenter, prospective, randomized clinical trial evaluating the healing efficacy of Algosteril® vs Aquacel Extra® in complete pilonidal sinus excisions

Acronym

ALPI

Study objectives

Algostéril is better than Aquacel Extra for the healing of the pilonidal sinus excision

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 21/04/2023, CPP Nord-Ouest IV (Bâtiment ex USNB- 6 rue du Pr Laguesse - CHRU Lille - CS70001, Lille, 59037, France; -; cppnordouestiv@univ-lille.fr), ref: 22.04704.000166

Study design

Multicenter prospective comparative randomized parallel-group open-label superiority study

Primary study design

Interventional

Study type(s)

Treatment, Efficacy

Health condition(s) or problem(s) studied

Pilonidal sinus

Interventions

Patients were randomized (Interactive Web Response System [IWRS]) during surgery after excision of the pilonidal sinus. According to the randomization, patients will be treated with Algostérial or Aquacel Extra. The dressing will be renewed by the nurse at the patient's home in accordance with the note to use. The duration of follow-up will be 6 weeks.

Intervention Type

Device

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Algostérial, Aquacel Extra

Primary outcome(s)

% of patients with complete excisional closure evaluated by the investigator at 6 weeks post-operative

Key secondary outcome(s)

1. % reduction of the excision volume measured by depth x area at weeks 3 and 6
2. Time in days between the date of surgery and resumption of normal activity, self-assessed by patient
3. Nature and frequency of Algostérial or Aquacel Extra-related incidents and adverse events (AEs) related to the investigation procedure, recorded using the adverse event form throughout the study

Completion date

01/07/2026

Eligibility

Key inclusion criteria

1. Adult with sacrococcygeal pilonidal sinus:
 - 1.1. Non-recurrent
 - 1.2. Who must undergo excision down to the fascia with an electric scalpel
 - 1.3. With an excision length of between 5 and 12 cm
 - 1.4. Which will be left to undergo directed healing
2. Which may be seen again as an outpatient at weeks 3 and 6

3. Affiliated with a social security scheme
4. Who have read and understood the information note and signed a written informed consent to participate in the clinical investigation

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Pilonidal sinus requiring simple flattening and/or with associated anal fistula
2. Verneuil disease and/or uncontrolled diabetes (> 2g/l)
3. Treated with long-term anti-inflammatory drugs, chemotherapy or immunocompromised
4. Undergoing or having undergone pelvic radiotherapy
5. Known to be allergic to constituents of study products
6. Concurrently participating in another study that may have an impact on wound healing
7. Pregnant or nursing woman
8. Person deprived of liberty by judicial or administrative decision or person subject to a legal protective measure

Date of first enrolment

01/08/2023

Date of final enrolment

01/04/2026

Locations**Countries of recruitment**

France

Study participating centre

GH Paris St Josphe

185 rue Raymond Losserand

Paris

France

75014

Study participating centre

Clinique Blomet

136bis rue Blomet

Paris

France

75015

Study participating centre

GH Diaconesses Croix St Simon

125 rue d'Avron

Paris

France

75020

Study participating centre

HIA Begin

69 avenue de Paris

saint Mandé

France

94160

Study participating centre

CU Grenoble Alpes

boulevard de la Chantourne

La Tronche

France

38700

Study participating centre

HIA Clermont-Tonnerre

Rue Colonel Fonferrier

Brest

France

29240

Study participating centre

MSP Bordeaux Bagatelle

203 route de Toulouse

Talence
France
33401

Study participating centre
Cabinet de proctologie
5 route de St Nazaire
Saint Herblain
France
44800

Study participating centre
CHI Poissy St Germain en Laye
10 rue du Champ Gaillard
Poissy
France
78303

Sponsor information

Organisation
Brothier (France)

ROR
<https://ror.org/007jkh405>

Funder(s)

Funder type
Industry

Funder Name
Brothier (France)

Results and Publications

Individual participant data (IPD) sharing plan

The data-sharing plans for the current study are unknown and will be made available at a later date

IPD sharing plan summary

Data sharing statement to be made available at a later date